Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans-Reference-Cited by-同舟云学术

Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans

Published:2021-08-19 Issue:2 Volume:379 Page:134-146
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Ayyar Vivaswath S.,Song Dawei,Zheng Songmao,Carpenter Thomas,Heald Donald L.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference61 articles.

1. Impact of serum proteins on the uptake and RNAi activity of GalNAc-conjugated siRNAs;Agarwal;Nucleic Acid Ther,2021

2. Akinc A Sehgal A Brodsky J Qin J Racie T Foster D Milstein S Barros S Hettinger J Panesar S (2012) RNAi-mediated inhibition of a natural anticoagulant for the treatment of hemophilia, in Proceedings of the 8th Annual Meeting of the Oligonucleotide Therapeutics Society, pp A9–A10, Oligonucleotide Therapeutics Society, San Diego, CA.

3. Spartan: a comprehensive tool for understanding uncertainty in simulations of biological systems;Alden;PLOS Comput Biol,2013

4. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids

5. Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model;Clinical Pharmacology & Therapeutics;2024-01-28

2. Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation;Journal of Pharmaceutical Sciences;2024-01

3. Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran;Journal of Pharmaceutical Sciences;2024-01

4. Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling;Expert Opinion on Drug Metabolism & Toxicology;2023-11-18

5. Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy;Journal of Pharmacokinetics and Pharmacodynamics;2023-10-17